Diabetes Clinical Trials in Arizona

Showing 401-420 of 495 trials

PGC-1 and Mitochondrial Dysfunction in Diabetes

NCT01724515

The purpose of this study is determine if you have too much fat in your body that it will decrease the conversion of food energy into energy that your body can use.

DiabetesObese

Mayo Clinic16 participantsStarted Sep 2012

Scottsdale, Arizona, United States

COMPLETEDPhase 331 miles

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome

NCT00968708

The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.

Diabetes Mellitus, Type 2Acute Coronary Syndrome

Takeda5,380 participantsStarted Sep 2009

Birmingham, Alabama, United States • Dothan, Alabama, United States • Mobile, Alabama, United States +905 more locations

PreviousPage 21 of 25Next

PGC-1 and Mitochondrial Dysfunction in Diabetes

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome

Diabetes Trials in Other Cities

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

The CareFUL Prevention Trial

Non-traditional Cardiovascular Risk Factors and Atherosclerosis in Type 2 Diabetes

Markers and Mechanisms of Vascular Disease in Type II Diabetes

Fatty Acid Binding Protein 2 (FABP2) Ancillary Proposal

Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients

Dapagliflozin DPPIV Inhibitor add-on Study

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes

Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy

Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy

Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions

Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies

Other Conditions in Arizona